Background/Aims: Factor V Leiden heterozygosity occurs in 3-8% of the general European and US populations. Activated protein C resistance (APC-R) - a non-molecular laboratory test - can efficiently demonstrate the presence of this mutation and can be performed on most coagulation analyzers. On the other hand, fistula or graft thrombosis is a common and costly complication in hemodialysis patients. Our aim was to establish the value of APC-R determination in hemodialysis patients by assessing the risk of access thrombosis in patients with increased APC-R. Methods: A total of 133 patients (81 men, mean age 64.5 ± 14.9 years and 52 women, mean age 63.6 ± 15 years) were selected. Participants were divided into 2 groups: those with access thrombosis (54 patients, 40.6%) and those with no access thrombosis (79 patients, 59.4%), and they were tested for the most common congenital or acquired thrombophilia risk factors. Results: Overall, 12 patients (9%) had an increased APC-R and 10 of them had at least 1 episode of access thrombosis (83.3%). Univariate analysis to estimate crude odds ratio (OR) showed an OR of 8.8 (95% CI 1.8-41.8) times higher risk for access thrombosis in these patients. No significant differences were found after adjusting for age, hypertension, diabetes mellitus, coronary artery disease, cerebrovascular disease, peripheral arterial disease and malignancy. Sex was also a factor influencing thrombosis, presenting a higher OR for women (OR 2.2, 95% CI 1.1-4.4). Conclusion: This study revealed a significant association between access thrombosis and increased APC-R in hemodialysis patients. This indicates that the determination of APC-R should be considered - especially, in populations with a high prevalence of Factor V Leiden - as proper anticoagulant therapy in these patients may reduce the risk of access thrombosis.

1.
Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-1008.
2.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
3.
Irani-Hakime N, Tamim H, Elias G, Finan RR, Daccache JL, Almawi WY: High prevalence of Factor V mutation (Leiden) in the eastern Mediterranean. Clin Chem 2000;46:134-136.
4.
Rees C, Cox M, Clegg B: World distribution of factor V Leiden. Lancet 1995;346:1133-1134.
5.
Jadaon MM: Epidemiology of prothrombin G20210A mutation in the Mediterranean region. Mediterr J Hematol Infect Dis 2011;3:e2011054.
6.
Ridker PM, Miletich JP, Hennekens CH, Buring JE: Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305-1307.
7.
Zöller B, Norlund L, Leksell H, Nilsson JE, von Schenck H, Rosén U, Jepsson JO, Dahlbäck B: High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996;83:475-477.
8.
Awidi A, Shannak M, Bseiso A, Kailani MA, Kailani MA, Omar N, Anshasi B, Sakarneh N: High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 1999;81:582-584.
9.
Lee DH, Henderson PA, Blajchman MA: Prevalence of factor V Leiden in a Canadian blood donor population. CMAJ 1996;155:285-289.
10.
Kapiotis S, Quehenberger P, Jilma B, Handler S, Pabinger-Fasching I, Mannhalter C, Speiser W: Improved characteristics of aPC-resistance assay: coatest aPC resistance by predilution of samples with factor V deficient plasma. Am J Clin Pathol 1996;106:588-593.
11.
United States Renal Data System: The economic cost of ESRD, vascular access procedures, and medicare spending for alternative modalities of treatment. USRDS. United States Renal Data System. Am J Kidney Dis 1997;30(2 suppl 1):S160-S177.
12.
Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis vascular access morbidity in the United States. Kidney Int 1993;43:1091-1096.
13.
Oger E, Leroyer C, Mercier B, Van Dreden P, Bressollette L, De Saint-Martin L, Le Moigne E, Blouch MT, Thuillier N, Amiral J, Ferec C, Abgrall JF, Mottier D: Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-R. Blood Coagul Fibrinolysis 1998;9:355-359.
14.
Bosman PJ, Boereboom FT, Eikelboom BC, Koomans HA, Blankestijn PJ: Graft flow as a predictor of thrombosis in hemodialysis grafts. Kidney Int 1998;54:1726-1730.
15.
Diskin CJ, Stokes TJ Jr, Pennell AT: Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron 1993;64:1-26.
16.
Bassiouny HS, White S, Glagov S, Choi E, Giddens DP, Zarins CK: Anastomotic intimal hyperplasia: mechanical injury or flow induced. J Vasc Surg 1992;15:708-716.
17.
Roberts AB, Kahn MB, Bradford S, Lee J, Ahmed Z, Fitzsimmons J, Ball D: Graft surveillance and angioplasty prolongs dialysis graft patency. J Am Coll Surg 1996;183:486-492.
18.
Safa A, Valji K, Roberts AC, Ziegler TW, Hye RJ, Oglevie SB: Detection and treatment of dysfunctional hemodialysis access grafts: effect of a surveillance program on graft patency and the incidence of thrombosis. Radiology 1996;199:653-657.
19.
Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC: Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989;80:1726-1736.
20.
Roy-Chaudhury P, Kelly BS, Miller MA, et al: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001;59:2325-2334.
21.
Bittl JA: Catheter interventions for hemodialysis fistulas and grafts. JACC Cardiovasc Interv 2010;3:1-11.
22.
Fekih-Mrissa N, Klai S, Bafoun A, Nciri B, Hmida J, Gritli N: Role of thrombophilia in vascular access thrombosis among chronic hemodialysis patients in Tunisia. Ther Apher Dial 2011;15:40-43.
23.
Almawi WY, Keleshian SH, Borgi L, Fawaz NA, Abboud N, Mtiraoui N, Mahjoub T: Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs. J Thromb Thrombolysis 2005;20:163-168.
24.
Maalej L, Hadjkacem B, Ben Amor I, Smaoui M, Gargouri A, Gargouri J: Prevalence of factor V Leiden in south Tunisian blood donors. J Thromb Thrombolysis 2011;32:116-119.
25.
Födinger M, Mannhalter C, Pabinger I, Koizar D, Rintelen C, Hörl WH, Sunder-Plassmann G: Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Nephrol Dial Transplant 1996;11:668-672.
26.
Crowther MA, Kelton JG: Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003;138:128-134.
27.
Van Cott EM, Laposata M: Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am 1998;12:1141-1166.
28.
Salmela B, Hartman J, Peltonen S, Albäck A, Lassila R: Thrombophilia and arteriovenous fistula survival in ESRD. Clin J Am Soc Nephrol 2013;8:962-968.
29.
Nampoory MR, Das KC, Johny KV, Al-Hilali N, Abraham M, Easow S, Saed T, Al-Muzeirei IA, Sugathan TN, Al Mousawi M: Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 2003;42:797-805.
30.
LeSar CJ, Merrick HW, Smith MR: Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 1999;189:73-79.
31.
Knoll GA, Wells PS, Young D, Perkins SL, Pilkey RM, Clinch JJ, Rodger MA: Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 2005;16:1108-1114.
32.
Molino D, De Lucia D, Marotta R, Perna A, Lombardi C, Cirillo M, De Santo NG: In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005;68:1223-1229.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.